DK2785744T3 - Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf - Google Patents

Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf

Info

Publication number
DK2785744T3
DK2785744T3 DK12853600.0T DK12853600T DK2785744T3 DK 2785744 T3 DK2785744 T3 DK 2785744T3 DK 12853600 T DK12853600 T DK 12853600T DK 2785744 T3 DK2785744 T3 DK 2785744T3
Authority
DK
Denmark
Prior art keywords
complement
procedures
protein inhibitors
vegf pathways
vegf
Prior art date
Application number
DK12853600.0T
Other languages
English (en)
Inventor
Jeng-Horng Her
Huang-Tsu Chen
Original Assignee
Innovent Biologics Inc
Ap Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Inc, Ap Biosciences Inc filed Critical Innovent Biologics Inc
Application granted granted Critical
Publication of DK2785744T3 publication Critical patent/DK2785744T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01112—Protein-tyrosine kinase (2.7.1.112)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
DK12853600.0T 2011-12-01 2012-11-30 Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf DK2785744T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629932P 2011-12-01 2011-12-01
PCT/US2012/067489 WO2013082563A1 (en) 2011-12-01 2012-11-30 Protein inhibitors to complement and vegf pathways and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2785744T3 true DK2785744T3 (da) 2017-11-27

Family

ID=48536152

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12853600.0T DK2785744T3 (da) 2011-12-01 2012-11-30 Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf

Country Status (10)

Country Link
US (2) US9988611B2 (da)
EP (1) EP2785744B1 (da)
JP (2) JP6138815B2 (da)
CN (2) CN110078831A (da)
AU (1) AU2012318288B2 (da)
BR (1) BR112014013205A2 (da)
CA (1) CA2857168C (da)
DK (1) DK2785744T3 (da)
ES (1) ES2651521T3 (da)
WO (1) WO2013082563A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104721820A (zh) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 双特异性单克隆抗体在治疗葡萄膜炎中的用途
PL3110434T3 (pl) * 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
KR102314088B1 (ko) * 2014-03-24 2021-10-15 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN105327346B (zh) * 2014-08-07 2019-10-18 信达生物制药(苏州)有限公司 一种单克隆抗体在治疗银屑病中的应用
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN106084062B (zh) * 2015-04-28 2021-04-02 荣昌生物制药（烟台）有限公司 桥连的双特异性融合蛋白
ES2797901T3 (es) 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CN106890313A (zh) * 2015-12-18 2017-06-27 信达生物制药(苏州)有限公司 用于治疗病理性近视的药物
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
CN121343934A (zh) * 2017-05-10 2026-01-16 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
SI3793586T1 (sl) * 2018-05-16 2024-07-31 Csl Limited Različice receptorja za topni komplement tipa 1 in njihova uporaba
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
CN112912104A (zh) * 2018-08-17 2021-06-04 三钰生物科技股份有限公司 抗血管新生融合蛋白及其用途
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2020213004A1 (en) * 2019-04-13 2020-10-22 National Centre For Cell Science Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076991A1 (en) * 2019-10-17 2021-04-22 Annexon, Inc. Compositions and methods for treating blood disorders
CN118750581A (zh) * 2019-12-24 2024-10-11 信达生物制药(苏州)有限公司 融合蛋白在治疗年龄相关性黄斑变性中的应用
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CA3189030A1 (en) * 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
MX2023004377A (es) * 2020-10-16 2023-06-28 Gyroscope Therapeutics Ltd Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad.
CN113041360A (zh) * 2021-04-01 2021-06-29 深圳廷美奥生物技术有限公司 一种用于治疗年龄相关性黄斑变性的药物
JP2024530951A (ja) * 2021-08-09 2024-08-27 ユアンプ バイオテクノロジー（ウーハン）カンパニー リミテッド 二重特異性融合ポリペプチド及びその応用
WO2023091875A1 (en) * 2021-11-19 2023-05-25 Ap Biosciences, Inc. Bi-functional fusion proteins to complement pathways and method of inhibiting bone resorption
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
JP2025505131A (ja) * 2022-01-29 2025-02-21 ペキン ユニバーシティ ファースト ホスピタル ＩｇＡプロテアーゼトランケート、ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途
CN116675777B (zh) * 2022-02-23 2025-07-08 中山光度生物医药有限公司 包含补体抑制结构域的多特异性配体结合分子及其用途
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
JP2025512062A (ja) * 2022-04-11 2025-04-16 ロンバイオ ファーマ（スーチョウ）カンパニー，リミティド 補体阻害ハイブリッドタンパク質
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
EP4617287A1 (en) 2022-11-10 2025-09-17 Longbio Pharma (Suzhou) Co., Ltd. Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
AU2023404417A1 (en) * 2022-11-28 2025-06-26 Shenzhen Oculgen Biomedical Technology Co., Ltd C5/vegf bispecific binding molecules
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024206379A1 (en) 2023-01-05 2025-07-24 Complement Therapeutics Limited Agents and methods for treating complement diseases
WO2024234244A1 (zh) 2023-05-15 2024-11-21 天辰生物医药(苏州)有限公司 偏向性补体抑制杂合蛋白
WO2025021112A1 (zh) * 2023-07-24 2025-01-30 佳吾益(北京)科技有限公司 开发mhc新抗原的工程化细胞
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator
WO2025109172A1 (en) * 2023-11-24 2025-05-30 Universität Ulm Complement modulator
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU691525B2 (en) * 1991-05-03 1998-05-21 Washington University Modified truncated complement system regulators
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2417900A1 (en) * 2000-08-01 2002-02-07 Amgen Inc. C3b/c4b complement receptor-like molecules and uses thereof
MXPA03007186A (es) * 2001-02-09 2005-07-01 Human Genome Sciences Inc Receptor de quimiocina de proteina g humana (ccr5) hdgnr10.
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
US20070155663A1 (en) 2003-03-24 2007-07-05 Rudolf Richter Use of chemokine receptor agonists for stem cell transplantation
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
AU2006279541A1 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX351152B (es) 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.
EP2433642B1 (en) * 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010067339A2 (en) 2008-12-11 2010-06-17 Korea Advanced Institute Of Science And Technology Fusion protein capable of binding vegf-a and tnf-alpha
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit

Also Published As

Publication number Publication date
CA2857168C (en) 2020-10-27
US20150079084A1 (en) 2015-03-19
ES2651521T3 (es) 2018-01-26
JP2015500811A (ja) 2015-01-08
CN104159926B (zh) 2019-02-01
CN110078831A (zh) 2019-08-02
EP2785744A4 (en) 2015-07-22
CA2857168A1 (en) 2013-06-06
US20180312819A1 (en) 2018-11-01
WO2013082563A8 (en) 2014-06-26
AU2012318288B2 (en) 2015-09-17
AU2012318288A1 (en) 2013-06-20
US9988611B2 (en) 2018-06-05
JP6138815B2 (ja) 2017-05-31
WO2013082563A1 (en) 2013-06-06
BR112014013205A2 (pt) 2020-10-27
CN104159926A (zh) 2014-11-19
EP2785744B1 (en) 2017-10-04
JP2017189167A (ja) 2017-10-19
EP2785744A1 (en) 2014-10-08
US11518984B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
DK2785744T3 (da) Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf
DK2950535T3 (da) Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand
CO6950481A2 (es) Inhibidores de proteínas quinasas
DK2857401T5 (da) HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME
DK2619576T3 (da) Midler og fremgangsmåder til forudsigelse af behandlingsrespons hos en cancerpatient
DK3409278T3 (da) Heterocykliske proteinkinaseinhibitorer
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2914575T3 (da) Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
DK2428450T3 (da) Doseringsmetode og doseringsindretning
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
CO6940421A2 (es) Inhibidores de neprilisina
DK2726092T3 (da) Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf
DK2685986T3 (da) Glucosylceramidsyntasehæmmer
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
CO6781518A2 (es) Inhibidores de neprilisina
LT2841428T (lt) Dnr-pk inhibitoriai
DK2970205T3 (da) JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
EP2782570A4 (en) HETEROCYCLIC INHIBITORS OF GLUTAMINASE
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
IL228311A0 (en) Protein kinase inhibitors